[go: up one dir, main page]

ES2184764T3 - Complejos de inclusion de taxol o taxotere o extracto de taxus formados por ciclodextrinas, su preparacion y utilizacion. - Google Patents

Complejos de inclusion de taxol o taxotere o extracto de taxus formados por ciclodextrinas, su preparacion y utilizacion.

Info

Publication number
ES2184764T3
ES2184764T3 ES94918994T ES94918994T ES2184764T3 ES 2184764 T3 ES2184764 T3 ES 2184764T3 ES 94918994 T ES94918994 T ES 94918994T ES 94918994 T ES94918994 T ES 94918994T ES 2184764 T3 ES2184764 T3 ES 2184764T3
Authority
ES
Spain
Prior art keywords
taxol
cyclodextrines
taxotere
preparation
inclusion complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94918994T
Other languages
English (en)
Inventor
Lajos Szente
Jozsef Szejili
Andrasne Vikmon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinoin Private Co Ltd
Original Assignee
Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt filed Critical Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Zrt
Application granted granted Critical
Publication of ES2184764T3 publication Critical patent/ES2184764T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Epoxy Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

LA INVENCION SE REFIERE A LOS COMPLEJOS DE INCLUSION DE TAXOL O TAXOTERE Y A LOS EXTRACTOS DE TAXUS (QUE CONTIENEN TAXOL Y OTROS DITERPENOS DERIVADOS DE TAXAN) ELABORADOS CON UN DERIVADO DE CICLODEXTRINA O UNA MEZCLA DE UN DERIVADO DE CICLODEXTRINA. SEGUN LA INVENCION, SE PUEDE CONSEGUIR UNA SOLUBILIDAD AL AGUA MEJORADA DEL TAXOL Y DE LOS DERIVADOS DEL TAXAN MEDIANTE EL USO DE LAS CICLODEXTRINAS Y/O DERIVADOS Y/O MEZCLAS DE CICLODEXTRINAS APROPIADAS. LOS COMPLEJOS DE INCLUSION PUEDEN SER PREPARADOS EN UN MEDIO ACUOSO, EN FORMA SOLIDA O MEDIANTE MOLIDO DE ALTA ENERGIA. LAS COMPOSICIONES FARMACEUTICAS SEGUN LA INVENCION TIENEN UNA IMPORTANCIA RELEVANTE EN EL TRATAMIENTO DEL CANCER.
ES94918994T 1993-05-12 1994-05-09 Complejos de inclusion de taxol o taxotere o extracto de taxus formados por ciclodextrinas, su preparacion y utilizacion. Expired - Lifetime ES2184764T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9301373A HU213200B (en) 1993-05-12 1993-05-12 The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production

Publications (1)

Publication Number Publication Date
ES2184764T3 true ES2184764T3 (es) 2003-04-16

Family

ID=10983581

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94918994T Expired - Lifetime ES2184764T3 (es) 1993-05-12 1994-05-09 Complejos de inclusion de taxol o taxotere o extracto de taxus formados por ciclodextrinas, su preparacion y utilizacion.

Country Status (23)

Country Link
US (1) US6284746B1 (es)
EP (1) EP0698018B1 (es)
JP (1) JP3693341B2 (es)
CN (1) CN1123030A (es)
AT (1) ATE225340T1 (es)
AU (1) AU693101B2 (es)
BG (1) BG100207A (es)
BR (1) BR9406292A (es)
CA (1) CA2162716C (es)
CZ (1) CZ291495A3 (es)
DE (1) DE69431476T2 (es)
DK (1) DK0698018T3 (es)
ES (1) ES2184764T3 (es)
FI (1) FI955424A0 (es)
HU (1) HU213200B (es)
IL (1) IL109613A (es)
NO (1) NO954545L (es)
OA (1) OA10323A (es)
PL (1) PL311561A1 (es)
PT (1) PT698018E (es)
SK (1) SK140595A3 (es)
WO (1) WO1994026728A1 (es)
YU (1) YU26894A (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009083793A1 (es) * 2007-12-28 2009-07-09 Universidad De Concepcion Complejo de inclusión formado por disulfiram y una ciclodextrina, útil en el tratamiento de la dependencia de alcohol y cocaína

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994341A (en) * 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
HUP9701945A3 (en) * 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
KR100669174B1 (ko) * 1998-02-05 2007-01-17 노파르티스 아게 유기화합물 함유 조성물
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
TWI321054B (en) * 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
GB0127677D0 (en) * 2001-11-19 2002-01-09 Vianex S A Inclusion complex
US20040106199A1 (en) * 2002-12-02 2004-06-03 Eliseev Alexey V. Charged cyclodextrin derivatives and their use in plant cell and tissue culture growth media
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
CN101278929B (zh) * 2007-04-02 2011-05-18 王效山 含有藤黄酸类化合物的药物及藤黄酸类化合物的包合物的制备方法
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
ITMI20071321A1 (it) * 2007-07-04 2009-01-05 Sea Marconi Technologies Di Va Nanospugne a base di ciclodestrine come veicolo per farmaci antitumorali
ES2464729T3 (es) 2008-08-21 2014-06-03 The Johns Hopkins University Procedimientos y composiciones para la administración de 3-halopiruvato y compuestos relacionados para el tratamiento del cáncer
WO2015108932A1 (en) * 2014-01-14 2015-07-23 The Johns Hopkins University Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof
CN103920163B (zh) * 2014-03-14 2016-09-14 南京大学 一种紫杉醇复合物、制备方法及其应用
EP3370712B1 (en) 2015-11-06 2025-02-19 The Johns Hopkins University 3-bromopyruvate for treating liver fibrosis
GB201715008D0 (en) * 2017-09-18 2017-11-01 Inst De Medicina Molecular Faculdade De Medicina Univ De Lisboa TRPV2 Antagonists
JP7274785B2 (ja) 2018-07-25 2023-05-17 ビカ バイオテクノロジー （グアンジョウ） カンパニー リミテッド 注射用ドセタキセル組成物およびそのための調製法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181703B (en) * 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
JPS62120324A (ja) * 1985-11-20 1987-06-01 Nippon Junyaku Kk 有機物質の水溶化方法
JP2651567B2 (ja) * 1986-03-20 1997-09-10 花王株式会社 メチル化β−シクロデキストリン
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
JP2929108B2 (ja) * 1988-10-28 1999-08-03 株式会社資生堂 化粧料および粉末化粧料
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
JPH02200671A (ja) * 1989-01-30 1990-08-08 Agency Of Ind Science & Technol インドールを抽出分離する方法およびインドール包接分離用薬剤
JPH035438A (ja) * 1989-05-31 1991-01-11 Kaken Pharmaceut Co Ltd フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
GB8920135D0 (en) * 1989-09-06 1989-10-18 Erba Carlo Spa Use of dehydrated cyclodextrins for improving drug dissolution
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
EP0485614B1 (en) * 1990-05-21 1997-08-13 Toppan Printing Co., Ltd. Cyclodextrin derivative
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5278324A (en) * 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
JPH06157330A (ja) * 1992-11-27 1994-06-03 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法と用途
JPH0753396A (ja) 1993-08-19 1995-02-28 Ensuiko Sugar Refining Co Ltd タキソールのサイクロデキストリン包接物，その製造法および用途
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009083793A1 (es) * 2007-12-28 2009-07-09 Universidad De Concepcion Complejo de inclusión formado por disulfiram y una ciclodextrina, útil en el tratamiento de la dependencia de alcohol y cocaína
ES2348887A1 (es) * 2007-12-28 2010-12-16 Universidad De Concepcion Complejo de inclusion formado por disulfiram y una ciclodextrina, util en el tratamiento de la dependencia de alcohol y cocaina.

Also Published As

Publication number Publication date
IL109613A (en) 1997-09-30
EP0698018A1 (en) 1996-02-28
ATE225340T1 (de) 2002-10-15
HU9301373D0 (en) 1993-09-28
OA10323A (en) 1997-10-07
DE69431476T2 (de) 2003-06-18
CA2162716C (en) 2005-03-08
DK0698018T3 (da) 2003-02-10
BG100207A (bg) 1996-05-31
PL311561A1 (en) 1996-02-19
FI955424L (fi) 1995-11-10
EP0698018B1 (en) 2002-10-02
HU213200B (en) 1997-03-28
BR9406292A (pt) 1995-12-26
US6284746B1 (en) 2001-09-04
AU7008194A (en) 1994-12-12
CA2162716A1 (en) 1994-11-24
HUT68589A (en) 1995-06-28
CN1123030A (zh) 1996-05-22
IL109613A0 (en) 1994-08-26
JPH08510232A (ja) 1996-10-29
NO954545D0 (no) 1995-11-10
JP3693341B2 (ja) 2005-09-07
CZ291495A3 (en) 1996-04-17
YU26894A (sh) 1997-05-28
NO954545L (no) 1995-11-10
WO1994026728A1 (en) 1994-11-24
SK140595A3 (en) 1996-10-02
DE69431476D1 (de) 2002-11-07
PT698018E (pt) 2003-02-28
AU693101B2 (en) 1998-06-25
FI955424A0 (fi) 1995-11-10

Similar Documents

Publication Publication Date Title
ES2184764T3 (es) Complejos de inclusion de taxol o taxotere o extracto de taxus formados por ciclodextrinas, su preparacion y utilizacion.
AR041023A1 (es) Composiciones y metodos para tratar el cancer usando inmunoconjugados de anticuerpo para cd44 citotoxicos y agentes quimioterapeuticos
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
PE20010053A1 (es) Formulacion de amoxicilina y clavulanato de potasio
SV1999000118A (es) Nuevos derivados de pirazol substituidos ref. lea 33188-sv
PA8453201A1 (es) Formulaciones farmaceuticas que contienen voriconazol
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
MX9308012A (es) Eteres fosfonooximetilicos de derivados de taxano, solubles en agua y composiciones farmaceuticas que los incluyen.
ES2049690T1 (es) Derivados de taxano, su preparacion y uso en oncologia.
MX9307011A (es) Derivados hidrosolubles de camptotecina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
DK1646608T3 (da) Tricykliske derivater eller farmaceutisk acceptable salte deraf, deres fremstillinger og farmaceutiske sammensætninger indeholdende dem
ATE248187T1 (de) Echinocandin-kohlenhydrate-komplexe
UY27018A1 (es) Derivados de la pirimidina
CY1108197T1 (el) Βελτιωμενες φαρμακευτικες συνταγοποιησεις αναστολεων πρωτεασης hiv
ES2088780T3 (es) Complejos de inclusion con silibinina, su preparacion y composiciones farmaceuticas que los contienen.
AR032455A1 (es) Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
ATE323483T1 (de) Pharmazeutische zusammensetzungen die acryloyl- substituierte distamycin-derivate und topoisomerase i und ii inhibitoren enthalten
UY27220A1 (es) Combinación de un taxano con una quinasa ciclina-dependiente
HN2001000021A (es) Nuevos derivados de amidas heterociclicas
PT1565176E (pt) Meio com uma accao destrutiva sobre tumores malignos e processo para produzi-lo
MX9400911A (es) Uso de inhibidores de ornitina aminotransferasa enel tratamiento de la demencia del tipo de alzheimer.
NO20020669L (no) Fenantrolin-7-on-derivater og deres terapeutiske anvendelser
ECSP045041A (es) Uso de una dosis especifica de fondaparinux sodio para el tratamiento de los sindromes coronarios agudos